Franco Sicuro
Psychiatry · Olivette, MONPI 1629159207
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,000 of the $16,762 with a category attached, or 65.6%. AbbVie accounts for 70.2% of it on its own, with 28 other manufacturers making up the rest. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 266 payments — averaging $63.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Avanir Pharmaceuticals, Inc.$1K
- Sunovion Pharmaceuticals Inc.$631
- Johnson & Johnson$536
- Otsuka America Pharmaceutical, Inc.$395
- Vanda Pharmaceuticals Inc.$374
- plus $2K from 23 others
Across 577 payments — averaging $3959.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$759K
- Teva Pharmaceuticals USA, Inc.$418K
- Genentech, Inc.$340K
- Eisai Inc.$288K
- Boehringer Ingelheim$116K
- Avanir Pharmaceuticals, Inc.$95K
- plus $269K from 6 others
What the payments were for
- Speaking & faculty fees$11,00066%
- Travel & lodging$1,3498%
- Food & beverage$4,22225%
- Education$1901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $11,766 |
| Avanir Pharmaceuticals, Inc. | 10 | $1,146 |
| Sunovion Pharmaceuticals Inc. | 35 | $631 |
| Johnson & Johnson | 25 | $536 |
| Otsuka America Pharmaceutical, Inc. | 27 | $395 |
| Vanda Pharmaceuticals Inc. | 20 | $374 |
| Teva Pharmaceuticals USA, Inc. | 18 | $336 |
| Validus Pharmaceuticals LLC | 16 | $220 |
| Alkermes, Inc. | 12 | $217 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $214 |
| Janssen Scientific Affairs, LLC | 1 | $128 |
| Neurocrine Biosciences, Inc. | 7 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $108 |
| Indivior Inc. | 4 | $83 |
| Lundbeck LLC | 5 | $77 |
| Eisai Inc. | 5 | $68 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $58 |
| MDD US Operations, LLC | 3 | $41 |
| Orexo US, Inc. | 2 | $41 |
| Genentech, Inc. | 1 | $40 |
| Adlon Therapeutics L.p. | 3 | $36 |
| Merck | 2 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Bausch Health US, LLC | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,762 in reported general payments places this provider in the 90th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Olivette
- Gregory MattingleySaint Charles$4.7M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Brian BarashKansas City$856K
- Casey ProughLees Summit$615K
- George GrossbergSaint Louis$501K
- Shahid InsafBranson$416K
- Ahmed TaranissiMexico$343K
- Ravdeep KhanujaPoplar Bluff$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.